Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I SAD study of olorofim in healthy males
NCT02142153Phase 1Completed
- Sponsor
- F2G
- Start
- Aug 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of olorofim in invasive aspergillosis (IA) (10 arms), sponsored by F2G. Primary endpoint: Number of Subjects With Adverse Events. Started Aug 2014; status: completed.
02
Drugs
olorofim
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT02142153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02142153.